Modified Linggui Zhugan Decoction Ameliorates Glycolipid Metabolism and Inflammation via PI3K-Akt/mTOR-S6K1/AMPK-PGC-1α Signaling Pathways in Obese Type 2 Diabetic Rats

Jia-pan SUN; Lin SHI; Fang WANG; Jian QIN; Bin KE

doi:10.1007/s11655-020-3285-2

Your Location：

Home >

Browse articles >

Modified Linggui Zhugan Decoction Ameliorates Glycolipid Metabolism and Inflammation via PI3K-Akt/mTOR-S6K1/AMPK-PGC-1α Signaling Pathways in Obese Type 2 Diabetic Rats

Original Article | Updated：2022-03-18

- Modified Linggui Zhugan Decoction Ameliorates Glycolipid Metabolism and Inflammation via PI3K-Akt/mTOR-S6K1/AMPK-PGC-1α Signaling Pathways in Obese Type 2 Diabetic Rats
- Chinese Journal of Integrative Medicine Vol. 28, Issue 1, Pages: 52-59(2022)
- Affiliations：
  
  1.Department of Traditional Chinese Medicine, the First Affiliated Hospital, Sun Yat-sen University, Guangzhou (510080),China
  2.Department of Traditional Chinese Medicine,Zhujiang Hospital of Southern Medical University, Guangzhou(510280), China
  3.Department of Oncology, the First Affiliated Hospital, Sun Yat-sen University, Guangzhou (510080), China
  4.Department of Traditional Chinese Medicine, the Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen (518107),Guangdong Province, China
  5.Department of VIP Ward, Sun Yat-sen University Cancer Center, Guangzhou (510060), China
- Author bio：
  
  Prof. KE Bin, E-mail: jackhorn@163.com
- Funds：
- DOI：10.1007/s11655-020-3285-2
  CLC：
- Published：01 January 2022，
  
  Published Online：19 November 2020，
  
  Accepted：21 September 2020
Scan for full text
Jia-pan SUN, Lin SHI, Fang WANG, et al. Modified Linggui Zhugan Decoction Ameliorates Glycolipid Metabolism and Inflammation via PI3K-Akt/mTOR-S6K1/AMPK-PGC-1α Signaling Pathways in Obese Type 2 Diabetic Rats. [J]. Chinese Journal of Integrative Medicine 28(1):52-59(2022)
DOI：

Jia-pan SUN, Lin SHI, Fang WANG, et al. Modified Linggui Zhugan Decoction Ameliorates Glycolipid Metabolism and Inflammation via PI3K-Akt/mTOR-S6K1/AMPK-PGC-1α Signaling Pathways in Obese Type 2 Diabetic Rats. [J]. Chinese Journal of Integrative Medicine 28(1):52-59(2022) DOI： 10.1007/s11655-020-3285-2.

摘要

目的:

探讨加味苓桂术甘汤(MLZD)对肥胖2型糖尿病大鼠的保护作用.

方法:

将50只Sprague-Dawley大鼠按随机数字表法分为正常组、肥胖2型糖尿病 (ob -T2DM)组、MLZD低剂量[MLDZ-L

4.625 g/(kg•d)]、MLZD中剂量[MLD-M

9.25 g/(kg•d)及MLZD高剂量[MLD-H

18.5 g/(kg•d)]组

每组10只大鼠. 干预4周后

收集大鼠血液样本及肝脏、胰腺、肌肉组织评估胰岛素抵抗、血脂、脂肪因子和炎症细胞因子水平. 此外

进一步研究磷脂酰肌醇3激酶(PI3K)-蛋白激酶B (PKB或Akt)/哺乳动物雷帕霉素靶蛋白(mTOR)-核糖体蛋白亚基6激酶1(S6K1)/ AMP活化蛋白激酶(AMPK)-过氧化物酶体增殖激活受体共激活剂1α (PGC-1α)通路的改变.

结果:

治疗4周后

与肥胖2型糖尿病大鼠比较

MLZD治疗可明显降低大鼠空腹血糖及胰岛素水平、胰岛素抵抗指数

提高胰岛素敏感指数

并呈现剂量依赖性改变(

0.05). 肥胖2型糖尿病大鼠血清总胆固醇、甘油三酯、低密度脂蛋白胆固醇及游离脂肪酸水平亦明显降低; 脂联素水平升高

瘦素、抵抗素、肿瘤坏死因子-α和白细胞介素-6水平降低(均

0.05或

0.01)

脂肪因子和炎症细胞因子水平得到较大改善. 此外

MLZD可调节PI3K-Akt/mTOR-S6K1/AMPK-PGC-1α通路

保护肝脏和胰腺组织结构.

结论:

MLZD可有效改善糖脂代谢和炎症反应

其作用可能与PI3K-Akt/mTOR-S6K1/AMPK-PGC-1α信号通路有关.

Abstract

Objective:

To investigate the protective effects of modified Linggui Zhugan Decoction (MLZD)

a traditional Chinese medicine formula

on obese type 2 diabetes mellitus (T2DM) rats.

Methods:

Fifty Sprague-Dawley rats were randomly divided into 5 groups by a random number table

including normal

obese T2DM (ob-T2DM)

MLZD low-dose [MLDZ-L

4.625 g/(kg•d)]

MLZD middle-dose [MLD-M

9.25 g/(kg•d) ] and MLZD high-dose [MLD-H

18.5 g/(kg•d)] groups

10 rats in each group. After 4-week intervention

blood samples and liver

pancreas

muscle tissues were collected to assess the insulin resistance (IR)

blood lipid

adipokines and inflammation cytokines. The alteration of phosphatidylinositol 3 kinase (PI3K)- protein kinase B (PKB or Akt)/the mammalian target of rapamycin (mTOR)-ribosome protein subunit 6 kinase 1 (S6K1)/AMP-activated protein kinase (AMPK)-peroxisome proliferator-activated receptor gamma coactivator 1 alpha (PGC-1α) pathways were also studied.

Results:

MLZD dose-dependently reduced fasting blood glucose

fasting insulin

homeostasis model of assessment for IR index and increased insulin sensitive index compared with ob-T2DM rats (

0.05). Similarly

total cholesterol

triglyceride

low-density lipoprotein cholesterol and free fatty acids were also decreased compared with ob-T2DM rats after 4-week treatment (

0.05 or

0.01). Improvements in adipokines and inflammatory cytokines were observed with a raised level of adiponectin and a reduced level of leptin

resistin

tumor necrosis factor-α and interleukin-6 (

0.05 or

0.01). MLZD regulated the PI3K-Akt/mTOR-S6K1/AMPK-PGC-1α pathways and restored the tissue structure of liver and pancreas (

0.05 or

0.01).

Conclusions:

MLZD ameliorated glycolipid metabolism and inflammation

which may be attributed to the regulation of PI3K-Akt/mTOR-S6K1/AMPK-PGC-1α pathways.

关键词

Keywords

Chinese medicineobesitytype 2 diabetes mellitusglycolipid metabolismadipokinesinflammation

references

Wright AK, Kontopantelis E, Emsley R, Buchan I, Sattar N, Rutter MK. Life expectancy and cause-specific mortality in type 2 diabetes: a population-based cohort study quantifying relationships in ethnic subgroups. Diabetes Care 2017;40:338-345.

Collaborators GBDO, Afshin A, Forouzanfar MH, Reitsma MB, Sur P, Estep K, et al. Health effects of overweight and obesity in 195 countries over 25 years. N Engl J Med 2017;377:13-27.

Chen Y, Copeland WK, Vedanthan R, Grant E, Lee JE,Gu D, et al. Association between body mass index and cardiovascular disease mortality in east Asians and south Asians: pooled analysis of prospective data from the Asia Cohort Consortium. BMJ 2013;347:f5446.

Global Burden of Metabolic Risk Factors for Chronic Diseases C, Lu Y, Hajifathalian K, Ezzati M, Woodward M, Rimm EB,et al. Metabolic mediators of the effects of body-mass index,overweight, and obesity on coronary heart disease and stroke:a pooled analysis of 97 prospective cohorts with 1.8 million participants. Lancet 2014;383:970-983.

Roden M, Shulman GI. The integrative biology of type 2 diabetes. Nature 2019;576:51-60.

Scherer PE. The many secret lives of adipocytes:implications for diabetes. Diabetologia 2019;62:223-232.

Zhang ZJ. Synopsis of Golden Chamber. Beijing: People's Medical Publishing House 2005;12:44-45.

Liu T, Yang LL, Zou L, Li DF, Wen HZ, Zheng PY, et al. Chinese medicine formula Lingguizhugan Decoction improves beta-oxidation and metabolism of fatty acid in high-fat-diet-induced rat model of fatty liver disease. Evid Based Complement Alternat Med 2013;2013:429738.

Liu MT, Huang YJ, Zhang TY, Tan LB, Lu XF, Qin J. Lingguizhugan Decoction attenuates diet-induced obesity and hepatosteatosis via gut microbiota. World J Gastroenterol 2019;25:3590-3606.

Zhu M, Hao S, Liu T, Yang L, Zheng P, Zhang L, et al.Lingguizhugan Decoction improves non-alcoholic fatty liver disease by altering insulin resistance and lipid metabolism related genes: a whole trancriptome study by RNA-Seq.Oncotarget 2017;8:82621-82631.

Yang Y, Li Q, Chen S, Ke B, Huang Y, Qin J. Effects of modified Lingguizhugan Decoction combined with weekend fasting on metabolic syndrome. J Tradit Chin Med 2014;34:48-51.

Vanhaesebroeck B, Whitehead MA, Piñeiro R. Molecules in medicine mini-review: isoforms of PI3K in biology and disease. J Molecul Med (Berlin, Germany) 2016;94:5-11.

Hemmings BA, Restuccia DF. PI3K-PKB/Akt pathway. Cold Spring Harb Perspect Biol 2012;4:a011189.

Nelson VL, Jiang YP, Dickman KG, Ballou LM, Lin RZ.Adipose tissue insulin resistance due to loss of PI3K p110alpha leads to decreased energy expenditure and obesity.Am J Physiol Endocrinol Metab 2014;306:E1205-E1216.

Yu C, Chen Y, Cline GW, Zhang D, Zong H, Wang Y,et al. Mechanism by which fatty acids inhibit insulin activation of insulin receptor substrate-1 (IRS-1)-associated phosphatidylinositol 3-kinase activity in muscle. J Biol Chem 2002;277:50230-502236.

Zhou H, Huang S. The complexes of mammalian target of rapamycin. Curr Protein Pept Sci 2010;11:409-424.

Dann SG, Selvaraj A, Thomas G. mTOR Complex1-S6K1 signaling: at the crossroads of obesity, diabetes and cancer. Trends Mol Med 2007;13:252-259.

Hardie DG, Ross FA, Hawley SA. AMPK: a nutrient and energy sensor that maintains energy homeostasis. Nature Rev Molecul Cell Bio 2012;13:251-262.

Wu H, Deng X, Shi Y, Su Y, Wei J, Duan H. PGC-1alpha,glucose metabolism and type 2 diabetes mellitus. J Endocrinol 2016;229:R99-R115.

Cork GK, Thompson J, Slawson C. Real talk: the inter-play between the mTOR, AMPK, and hexosamine biosynthetic pathways in cell signaling. Front Endocrinol (Lausanne)2018;9:522.

Salmanoglu DS, Gurpinar T, Vural K, Ekerbicer N,Dariverenli E, Var A. Melatonin and L-carnitin improves endothelial disfunction and oxidative stress in type 2 diabetic rats. Redox Biol 2016;8:199-204.

Nair AB, Jacob S. A simple practice guide for dose conversion between animals and human. J Basic Clin Pharm 2016;7:27-31.

Bray GA, Heisel WE, Afshin A, Jensen MD, Dietz WH, Long M, et al. The science of obesity management: an Endocrine Society Scientific Statement. Endocr Rev 2018;39:79-132.

Samuel VT, Petersen KF, Shulman GI. Lipid-induced insulin resistance: unravelling the mechanism. Lancet 2010;375:2267-2277.

Ghadge AA, Khaire AA. Leptin as a predictive marker for metabolic syndrome. Cytokine 2019;121:154735.

Su KZ, Li YR, Zhang D, Yuan JH, Zhang CS, Liu Y, et al.Relation of circulating resistin to insulin resistance in type 2 diabetes and obesity: a systematic review and meta-analysis. Front Physiol 2019;10:1399.

Chakraborti CK. Role of adiponectin and some other factors linking type 2 diabetes mellitus and obesity. World J Diabetes 2015;6:1296-1308.

Perseghin G, Petersen K, Shulman GI. Cellular mechanism of insulin resistance: potential links with inflammation. Intern J Obesity Relat Metab Disord 2003:S6-S11.

Alzamil H. Elevated serum TNF-α is related to obesity in type 2 diabetes mellitus and is associated with glycemic control and insulin resistance. J Obesity 2020;2020:5076858.

Bertin E, Nguyen P, Guenounou M, Durlach V, Potron G,Leutenegger M. Plasma levels of tumor necrosis factor-alpha(TNF-alpha) are essentially dependent on visceral fat amount in type 2 diabetic patients. Diabet Metab 2000;26:178-182.

Lowe G, Woodward M, Hillis G, Rumley A, Li Q, Harrap S, et al. Circulating inflammatory markers and the risk of vascular complications and mortality in people with type 2 diabetes and cardiovascular disease or risk factors: the ADVANCE study. Diabetes 2014;63:1115-1123.

Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM.C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001;286:327-334.

Qu D, Liu J, Lau CW, Huang Y. IL-6 in diabetes and cardiovascular complications. Br J Pharmacol 2014;171:3595-3603.

Chen Y, Wu Y, Gan X, Liu K, Lv X, Shen H, et al.Iridoid glycoside from Cornus officinalis ameliorated diabetes mellitus-induced testicular damage in male rats:involvement of suppression of the AGEs/RAGE/p38 MAPK signaling pathway. J Ethnopharmacol 2016;194:850-860.

Jeftic I, Jovicic N, Pantic J, Arsenijevic N, Lukic ML,Pejnovic N. Galectin-3 ablation enhances liver steatosis,but attenuates inflammation and IL-33-dependent fibrosis in obesogenic mouse model of nonalcoholic steatohepatitis.Mol Med 2015;21:453-465.

Song Z, Guo Y, Zhou M, Zhang X. The PI3K/p-Akt signaling pathway participates in calcitriol ameliorating podocyte injury in DN rats. Metabolism 2014;63:1324-1333.

Huang X, Liu G, Guo J, Su Z. The PI3K/AKT pathway in obesity and type 2 diabetes. Int J Biol Sci 2018;14:1483-1496.

Ke B, Ke X, Wan X, Yang Y, Huang Y, Qin J, et al.Astragalus polysaccharides attenuates TNF-alpha-induced insulin resistance via suppression of miR-721 and activation of PPAR-gamma and PI3K/AKT in 3T3-L1 adipocytes. Am J Transl Res 2017;9:2195-2206.

Yan F, Dai G, Zheng X. Mulberry anthocyanin extract ameliorates insulin resistance by regulating PI3K/AKT pathway in HepG2 cells and db/db mice. J Nutr Biochem 2016;36:68-80.

Mishra AK, Dingli D. Metformin inhibits IL-6 signaling by decreasing IL-6R expression on multiple myeloma cells.Leukemia 2019;33:2695-2709.

Castilla-Madrigal R, Barrenetxe J, Moreno-Aliaga MJ,Lostao MP. EPA blocks TNF-alpha-induced inhibition of sugar uptake in Caco-2 cells via GPR120 and AMPK. J Cell Physiol 2018;233:2426-2433.

Wang Y, Shi M, Fu H, Xu H, Wei J, Wang T, et al. Mammalian target of the rapamycin pathway is involved in non-alcoholic fatty liver disease. Mol Med Rep 2010;3:909-915.

Liu L, Yao L, Wang S, Chen Z, Han T, Ma P, et al. 6-Gingerol improves ectopic lipid accumulation, mitochondrial dysfunction, and insulin resistance in skeletal muscle of ageing rats: dual stimulation of the AMPK/PGC-1α signaling pathway via plasma adiponectin and muscular adipoR1. Molecul Nutrit Food Res 2019;63:e1800649.

Minokoshi Y, Kim YB, Peroni OD, Fryer LG, Muller C, Carling D, et al. Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase. Nature 2002;415:339-343.

More>

Views

Downloads

CSCD

Alert me when the article has been cited

Submit

Tools

Publicity Resources

Inflammatory and Immunomodulatory Effects of Tripterygium wilfordii Multiglycoside in Mouse Models of Psoriasis Keratinocytes

Schisandrin B Protects against Ischemic Brain Damage by Regulating PI3K/AKT Signaling in Rats

Polypeptide from Moschus Suppresses Lipopolysaccharide-Induced Inflammation by Inhibiting NF-κB-ROS/NLRP3 Pathway

Anti-inflammatory Effects of Ampelopsis Japonica Root on Contact Dermatitis in Mice

Schisandrin B Inhibits NLRP3 Inflammasome Pathway and Attenuates Early Brain Injury in Rats of Subarachnoid Hemorrhage

Related Author

No data

Related Institution

Department of Dermatology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine

Institute of Dermatology, Shanghai Academy of Traditional Chinese Medicine

Department of Integrated Traditional Chinese and Western Medicine, Shanghai Skin Disease Hospital, Tongji University School of Medicine

Department of Neurology, The First Hospital of Quanzhou Affiliated to Fujian Medical University

Department of Neurosurgery, Fujian Medical University Union Hospital

Address：1 Caochang, xiyuan, Beijing, People's Republic of China Postal code：100091
Tel：010-62886827, 62877592 Fax：010-62874291
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备05067934号-1 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰